作者
Mikhail Kosiborod, Suzanne V Arnold, John A Spertus, Darren K McGuire, Yan Li, Patrick Yue, Ori Ben-Yehuda, Amos Katz, Philip G Jones, Ann Olmsted, Luiz Belardinelli, Bernard R Chaitman
发表日期
2013/5/21
期刊
Journal of the American College of Cardiology
卷号
61
期号
20
页码范围
2038-2045
出版商
American College of Cardiology Foundation
简介
Objectives
This study sought to examine the efficacy of ranolazine versus placebo on weekly angina frequency and sublingual nitroglycerin use in subjects with type 2 diabetes mellitus, coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment with up to 2 antianginal agents.
Background
Patients with diabetes have more extensive CAD than those without diabetes, and a high burden of angina. Ranolazine is not only effective in treating angina but also may improve glycemic control, thus providing several potential benefits in this high-risk group. We conducted a randomized trial to test the antianginal benefit of ranolazine in patients with diabetes and stable angina.
Methods
TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patients with diabetes …
学术搜索中的文章
M Kosiborod, SV Arnold, JA Spertus, DK McGuire, Y Li… - Journal of the American College of Cardiology, 2013